Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sulfonylureas in NIDDM.

L C Groop1

  • 1Fourth Department of Medicine, Helsinki University Hospital, Finland.

Diabetes Care
|June 1, 1992
PubMed
Summary
This summary is machine-generated.

Sulfonylureas effectively lower blood glucose by stimulating insulin secretion in type 2 diabetes patients with preserved beta-cell function. Rational use requires careful consideration of patient selection, dosage, and treatment duration for optimal glycemic control.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The link between family history and risk of type 2 diabetes is not explained by anthropometric, lifestyle or genetic risk factors: the EPIC-InterAct study.

Diabetologia·2012
Same author

Common variants in CNDP1 and CNDP2, and risk of nephropathy in type 2 diabetes.

Diabetologia·2011
Same author

A family history of diabetes is associated with reduced physical fitness in the Prevalence, Prediction and Prevention of Diabetes (PPP)-Botnia study.

Diabetologia·2010
Same author

Interaction between prenatal growth and high-risk genotypes in the development of type 2 diabetes.

Diabetologia·2009
Same author

Common variants in the TCF7L2 gene help to differentiate autoimmune from non-autoimmune diabetes in young (15-34 years) but not in middle-aged (40-59 years) diabetic patients.

Diabetologia·2008
Same author

HLA-DQB1 genotypes, islet antibodies and beta cell function in the classification of recent-onset diabetes among young adults in the nationwide Diabetes Incidence Study in Sweden.

Diabetologia·2006
Same journal

A Secular Increase in the Incidence of Islet Autoimmunity Among Colorado Children With Moderate-Risk HLA Genotypes.

Diabetes care·2026
Same journal

Clinical and Biochemical Recovery From Immune Checkpoint Inhibitor-Induced Diabetes With Seroconversion of GAD Antibodies.

Diabetes care·2026
Same journal

State Insulin Out-of-Pocket Cap Policies and Estimated Eligible Populations in the United States, 2019-2026.

Diabetes care·2026
Same journal

Genetic Determinants of Macronutrient Intake Are Associated With Specific Food Intake in Youth: A Cohort Study Across Childhood and Adolescence.

Diabetes care·2026
Same journal

A Novel Electronic Medical Record Search Method to Identify Patients With Ketosis-Prone Diabetes: Implications for Discovery of Atypical Diabetes.

Diabetes care·2026
Same journal

Real-Time Continuous Glucose Monitoring Among People With Type 2 Diabetes and End-Stage Kidney Failure Undergoing Maintenance Hemodialysis: A Randomized Clinical Trial.

Diabetes care·2026
See all related articles

Area of Science:

  • Endocrinology
  • Pharmacology
  • Metabolic Diseases

Background:

  • Sulfonylureas are a foundational oral therapy for type 2 diabetes mellitus (T2DM).
  • Despite decades of use, the precise mechanisms of action and optimal application of sulfonylureas remain incompletely understood.
  • Current clinical practice often deviates from rational therapeutic principles.

Purpose of the Study:

  • To critically evaluate the efficacy and limitations of sulfonylurea agents in T2DM management.
  • To identify key factors for rationalizing the clinical use of sulfonylureas.
  • To emphasize the importance of patient selection, dosing, and treatment duration.

Main Methods:

  • Review of existing literature on sulfonylurea pharmacology and clinical trials.

Related Experiment Videos

  • Analysis of evidence regarding extrapancreatic effects and beta-cell function dependency.
  • Examination of current prescribing patterns and dose-response relationships.

    • Main Results:

    • Sulfonylureas primarily lower blood glucose by stimulating insulin secretion, with limited evidence for significant extrapancreatic effects.
    • Therapeutic efficacy is largely confined to patients with preserved beta-cell function, particularly in early T2DM stages.
    • There is a lack of evidence supporting a dose-response relationship for sulfonylureas, and treatment is often initiated late or continued inappropriately.
    • Dosage escalation beyond recommended levels does not appear to enhance biological effects.

    Conclusions:

    • Rational sulfonylurea therapy necessitates careful patient selection (preserved beta-cell function, early disease stage).
    • Optimal use requires judicious decisions regarding 'whom to treat, how much to administer, and for how long'.
    • Discontinuation of sulfonylurea treatment is as critical as its initiation for effective T2DM management.